NOVEL AND EFFICIENT METHOD OF ANTICANCER DRUG DELIVERY

Information

  • Research Project
  • 2422924
  • ApplicationId
    2422924
  • Core Project Number
    R44CA062905
  • Full Project Number
    2R44CA062905-02A2
  • Serial Number
    62905
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/13/1995 - 29 years ago
  • Project End Date
    9/29/1999 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1997 - 26 years ago
  • Budget End Date
    9/29/1998 - 25 years ago
  • Fiscal Year
    1997
  • Support Year
    2
  • Suffix
    A2
  • Award Notice Date
    9/15/1997 - 26 years ago
Organizations

NOVEL AND EFFICIENT METHOD OF ANTICANCER DRUG DELIVERY

The long term objective of this program is the development of effective therapies for treatment of solid malignant tumors. Electrochemotherapy (ECT) combines electroporation with very low doses of antitumor agents and has been shown to enhance the effectiveness of drugs. This phase II proposal will continue the systematic development of ECT that was initiated in Phase I. The focus will be on the following specific aims: (i) examine the distribution of the electric field in and around the tumor, (ii) determine if ECT can be used to enhance the effectiveness of several antitumor agents, (iii) optimization of electroporation parameters for in vivo animal studies with different drugs, (iv) continue the limited but highly encouraging clinical study to test this delivery system using the newly developed needle array, (v) develop instrumentation that will be sued in the treatment of caner patients. The completion of these aims will lead to the development of instruments for use in laboratory animals and in humans. The latter will be finished a the end of Phase II and will be suitable for treating skin cancer in humans in Phase III. PROPOSED COMMERCIAL APPLICATION: Permeabilizing a tumor cell membrane permits rapid uptake of a chemotherapeutic agent and enhances cytoxicity. This research will develop in year 1 hardware suitable for use by the research community for treating malignant tumors on small animals; year 2 work will finalize hardware for use in patients. Attractive features will include greater drug efficacy and an absence of systemic side effects due to local delivery of very low drug dosage.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    GENETRONICS, INC.
  • Organization Department
  • Organization DUNS
    122735749
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921211318
  • Organization District
    UNITED STATES